Costs Associated With 4 Months of Rifampin vs 9 Months of Isoniazid in Latent TB
Health system use and costs higher for 9 months of isoniazid vs 4 months of rifampin in adults and children in all settings.
Tuberculosis
Unsuccessful Treatment Outcomes in Nontuberculosis Mycobacteria Lung Disease
Approximately one-third of adults who undergo treatment for nontuberculosis mycobacteria lung disease experience an unsuccessful outcome, with adverse events and treatment discontinuation being major challenges.
Tuberculosis Alone and With HIV Co-Infection: Treatment Updates
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
QuantiFERON-TB Gold Plus Comparable to Other Assays for Incident Tuberculosis
QuantiFERON-TB Gold Plus was comparable to other interferon gamma release assays for predicting tuberculosis in adults with recent contacts.
Incidence of Tuberculosis High in Children Exposed to the Disease
Preventive therapy was effective in most children with tuberculosis if given before development of active disease.
Survey: Management of Amikacin Liposome Inhalation Suspension-Associated Respiratory Adverse Events
Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea.
Updated Guidelines for Latent TB Infection Treatment Released by CDC and NTCA
The National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention have released updated guidelines for the treatment of latent tuberculosis infection.
Normal Dose Moxifloxacin Maintained Effectiveness in Rifampin-Resistant TB
A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.
Early Bactericidal Activity of High-Dose Isoniazid for Drug Resistant TB
Daily doses of 10 to 15 mg/kg isoniazid demonstrated similar activity against tuberculosis (TB) strains with inhA mutations as 5 mg/kg doses against drug-sensitive strains.
Rifampicin May Be Safer Than Isoniazid in Latent Tuberculosis Treatment
In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection.
-
Loading...
-
Loading...
Next post in Tuberculosis
